Literature DB >> 15722704

Impacts of a government-sponsored outpatient-based disease management program for patients with asthma: a preliminary analysis of national data from Taiwan.

Hui-Ching Weng1.   

Abstract

In response to the high prevalence rates, mortality rates, and rising medical cost of asthma, the Bureau of National Health Insurance (BNHI) initiated a Healthcare Quality Improvement Program (HQIP) for people with asthma. The aim of this study was to investigate a preliminary analysis of the impact of a government-sponsored, outpatient-based disease management programs for people with asthma on the economic outcomes, the physician's and the patient's satisfaction. Using a retrospective design, a 1:4 (intervention vs. control group) matched cohort study design was used. Comparison of 1-year pre/post tests of utilizations of healthcare resources were conducted for 854 already diagnosed cases of patients with asthma. Comparison of independent tests between the intervention group and control group were performed for already diagnosed cases (n = 854) and newly-diagnosed cases (n = 231). Valid surveys were received from 212 physicians who participated the program, for a response rate of 46.0%, and 642 patients who enrolled in the program, for a response rate of 27.70%. Results indicated that the intervention group of already diagnosed cases had 39.94% fewer ED visits, 46.31% fewer inpatient visits, and 51.74% shorter length of stay, at a significant level. Though the HQIP program for people with asthma appeared to reduce medical care resource utilization for the intervention group, the control groups showed similar reductions but in different magnitude. For the newly diagnosed group, the intervention group had 197.43% more outpatient visits and 61.19% fewer ED visits of than those of the control group at a significant level. A majority of physicians (70%-85%) had positive opinions toward the HQIP program, but they admitted that the HQIP program prolonged the consultation time in outpatient visits (79.1%), and only 29.7% physicians did not feel interfered with while carrying out the HQIP. More than 80% of the patients showed positive feedback to the HQIP. The majority of the patients substantially adhered to physicians' suggestions, and had more accurate knowledge of and better self-care skills concerning asthma. These results have significance for the design of future programs aimed at improving the care of people with asthma and other chronic diseases in BNHI, Taiwan.

Entities:  

Mesh:

Year:  2005        PMID: 15722704     DOI: 10.1089/dis.2005.8.48

Source DB:  PubMed          Journal:  Dis Manag        ISSN: 1093-507X


  6 in total

1.  Health care utilization and medical costs for childhood asthma in Taiwan: using Taiwan National Health Insurance Research Database.

Authors:  Jiu-Yao Wang; Li-Fan Liu
Journal:  Asia Pac Allergy       Date:  2012-07-25

2.  Comparison of alternative risk adjustment measures for predictive modeling: high risk patient case finding using Taiwan's National Health Insurance claims.

Authors:  Hsien-Yen Chang; Wui-Chiang Lee; Jonathan P Weiner
Journal:  BMC Health Serv Res       Date:  2010-12-20       Impact factor: 2.655

3.  Comparison of the effects of air pollution on outpatient and inpatient visits for asthma: a population-based study in Taiwan.

Authors:  Hui-Hsien Pan; Chun-Tzu Chen; Hai-Lun Sun; Min-Sho Ku; Pei-Fen Liao; Ko-Hsiu Lu; Ji-Nan Sheu; Jing-Yang Huang; Jar-Yuan Pai; Ko-Huang Lue
Journal:  PLoS One       Date:  2014-05-01       Impact factor: 3.240

Review 4.  Adding non-randomised studies to a Cochrane review brings complementary information for healthcare stakeholders: an augmented systematic review and meta-analysis.

Authors:  Chantal Arditi; Bernard Burnand; Isabelle Peytremann-Bridevaux
Journal:  BMC Health Serv Res       Date:  2016-10-21       Impact factor: 2.655

Review 5.  What Taiwan contributes to the world of allergy and clinical immunology?

Authors:  Jiu-Yao Wang
Journal:  Asia Pac Allergy       Date:  2013-10-31

6.  Integrated traditional Chinese medicine for childhood asthma in Taiwan: a Nationwide cohort study.

Authors:  Yu-Chiang Hung; I-Ling Hung; Mao-Feng Sun; Chih-Hsin Muo; Bei-Yu Wu; Ying-Jung Tseng; Wen-Long Hu
Journal:  BMC Complement Altern Med       Date:  2014-10-10       Impact factor: 3.659

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.